TUESDAY, Oct. 1, 2024 -- Upward trends in breast cancer incidence among women have continued, according to a study published online Oct. 1 in CA: A...

WEDNESDAY, Oct. 2, 2024 -- For patients undergoing breast reconstruction, a 16-fraction course of hypofractionated postmastectomy radiation therapy...

THURSDAY, Sept. 19, 2024 -- For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by...

TUESDAY, Oct. 1, 2024 -- The 2023 cisplatin shortage led to a shift in utilization to alternative therapies for head and neck cancer (HNC), resulting...

TUESDAY, Oct. 1, 2024 -- While women overall are less likely to die of breast cancer now, some alarming disparities remain, a new American Cancer...

A study on exercise for cancer patients, presented at ESMO 2024, draws on data from the Breast Cancer Weight Loss (BWEL) trial. This trial is...

WEDNESDAY, Oct. 2, 2024 -- Circulating antibodies against cancer-testis antigens (CTAgs) are found in stage I and stage II melanoma plasma samples,...

In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates than white patients,...

Oncolytics Biotech (TSX:ONC) revealed results from its Phase 2 study in patients with advanced or metastatic breast cancer.

Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with...